Sommario
La melatonina regolarizza i ritmi circadiani sonno-veglia, il tono dell’umore e sembra avere un ruolo protettivo sul rischio di carcinogenesi. Questo ormone viene utilizzato nella terapia dei disturbi del sonno e del tono dell’umore che spesso colpiscono sia i pazienti oncologici, sia gli anziani, sia chi svolge un lavoro notturno. Nella presente review vengono riportati i principali lavori scientifici in vitro, nel modello animale e nell’uomo in merito a questi argomenti.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Claustrat B, Brun J, Chazot G (2005) The basic physiology and pathophysiology of melatonin. Sleep Med Rev 9:11–24
Tzischinsky O, Shlitner A, Lavie P (1993) The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulphatoxymelatonin. J Biol Rhythms 8:199–209
Jan JE, Reiter RJ, Wasdell MB, Bax M (2009) The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 46:1–7
Rondanelli M, Opizzi A, Monteferrario F et al. (2011) The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc 59:82–90
Srinivasan V, Smits M, Spence W et al. (2006) Melatonin in mood disorders. World J Biol Psychiatry 7:138–151
Straif K, Baan R, Grosse Y et al. (2007) Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 8:1065–1066
Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 3:13–22
Leonardi GC, Rapisarda V, Marconi A et al. (2012) Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). Oncol Rep 28:418–428
Hansen MV, Madsen MT, Hageman I et al. (2012) The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial. BMJ Open 2:e000647
Mills E, Wu P, Seely D, Guyatt G (2005) Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39:360–366
Rondanelli M, Faliva MA, Perna S, Antoniello N (2013) Update on the role of melatonin in the prevention of cancer tumorigenesis and management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res 25:499–510
Wang YM, Jin BZ, Ai F et al. (2012) The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 69:1213–1220
Conflitto di interesse
Gli autori Mariangela Rondanelli, Simone Perna, Maurizio Naso, Milena Faliva, Erica Repaci, Raffaella Pozzi, Francesca Monteferrario e Francesca Allieri dichiarano di non avere conflitti di interessi.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Author information
Authors and Affiliations
Corresponding author
Additional information
Proposta da Marco Federghini.
Materiale elettronico supplementare
Rights and permissions
About this article
Cite this article
Rondanelli, M., Perna, S., Naso, M. et al. Review sul ruolo della melatonina nella prevenzione del cancro e nella gestione delle comorbilità cancro-correlate, quali i disturbi del ritmo sonno-veglia e del tono dell’umore. L'Endocrinologo 15, 179–185 (2014). https://doi.org/10.1007/s40619-014-0059-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-014-0059-0